• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The functional analysis of Wilms' tumor 1 (WT1) variants in ovarian cancer

Research Project

Project/Area Number 15K20124
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Obstetrics and gynecology
Research InstitutionYamagata University

Principal Investigator

YAMANOUCHI Keiko  山形大学, 医学部, 非常勤講師 (00594318)

Project Period (FY) 2015-04-01 – 2017-03-31
Project Status Completed (Fiscal Year 2016)
Budget Amount *help
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
KeywordsWilms' tumor 1 (WT1) / WT1 variant / 小胞体ストレス / 薬剤耐性 / 卵巣癌 / WT1 / 細胞増殖 / 腫瘍産生能
Outline of Final Research Achievements

The Wilms’tumor 1 gene WT1 encodes a zinc transcription factor involved in cancer-related processes. WT1 is spliced alternatively at two sites: exon 5 with 17AA and the KTS site, which exists between exons 9 and 10. Splicing at these sites yields four variants (-17AA/-KTS, +17AA/-KTS, -17AA/+KTS, and +17AA/+KTS). Forced expression of WT1 -17AA/-KTS in SKOV3ip1 cells resulted in an increase in cell proliferation compared with the control. Overexpression of -17AA/-KTS resulted in a significant increase in the disseminated tumor weight, as compared with that in tumors expressing the control vector. However, there is no correlation between WT1 variants and drug sensitivity. In response to stress such as chemotherapy, cancer cell often activate the endoplasmic reticulum (ER) stress sensor, the unfolded protein response (UPR). The drug inducing UPR inhibited cell proliferation in ovarian cancer cells. Further studies are needed to clarify the relation between UPR and drug sensitivity.

Report

(3 results)
  • 2016 Annual Research Report   Final Research Report ( PDF )
  • 2015 Research-status Report

URL: 

Published: 2015-04-16   Modified: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi